List of Excipients in Branded Drug TAYTULLA

« Back to Dashboard

TAYTULLA Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Taytulla is an oral combined hormonal contraceptive containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg in 24 active capsules, followed by four ferrous fumarate capsules. Its commercial differentiation comes from the 24/4 capsule regimen, low-dose hormone uniformity, capsule-based delivery, and iron-containing placebo interval rather than from a novel active ingredient.[1]

The strongest excipient opportunities are low-dose content uniformity, capsule-fill robustness, moisture and light protection, iron-placebo compatibility, and reformulation into lower-cost or patient-preferred dosage forms. Generic competition is technically feasible, but formulation development must control microgram-level ethinyl estradiol distribution and maintain the labeled regimen, dissolution profile, stability, and capsule appearance.

What is the Taytulla formulation and how do its excipients function?

Taytulla uses a 28-capsule regimen:

Capsule type	Days	Active ingredients	Primary formulation objective
Active capsule	1-24	Norethindrone acetate 1 mg; ethinyl estradiol 20 mcg	Uniform delivery of two low-dose hormones
Iron capsule	25-28	Ferrous fumarate 75 mg, equivalent to approximately 24.75 mg elemental iron	Placebo interval with iron supplementation

The FDA labeling identifies lactose monohydrate, magnesium stearate, pregelatinized starch, and talc among the inactive ingredients used in the product. The capsule shells contain gelatin and colorants, including titanium dioxide and other permitted coloring agents.[1] Exact excipient quantities are generally not disclosed in public product labeling.

Functional role of the core excipients

Excipient class	Likely role in Taytulla	Development considerations
Lactose monohydrate	Diluent and bulking agent	Supports capsule fill weight and powder handling
Pregelatinized starch	Binder, disintegrant, and flow aid	Helps achieve rapid capsule opening and dispersion
Magnesium stearate	Lubricant	Excess use can slow wetting and dissolution
Talc	Glidant or anti-adherent	Requires control for flow, segregation, and regulatory specifications
Gelatin	Capsule shell	Provides immediate-release capsule delivery
Titanium dioxide and other colorants	Product identification and regimen differentiation	Color consistency and global regulatory status require review
Ferrous fumarate	Active placebo-period ingredient	Adds iron compatibility and elemental iron assay requirements

Taytulla is not a conventional placebo-controlled oral contraceptive pack. The last four capsules contain ferrous fumarate. That design creates additional manufacturing, packaging, labeling, and supply-chain requirements compared with a 24/4 blister containing inert placebo capsules.

What excipient strategy is required for low-dose hormone capsules?

The principal technical challenge is not capsule manufacture. It is achieving reproducible distribution of 20 mcg of ethinyl estradiol through the active blend and into every capsule.

Content uniformity

Ethinyl estradiol is present at a very low concentration relative to the total capsule fill. A commercial developer must control:

• Particle-size distribution of ethinyl estradiol.
• Geometric dilution and premixing sequence.
• Powder segregation during transfer and encapsulation.
• Static charge and adhesion to processing equipment.
• Sampling plans capable of detecting localized hormone variation.
• Blend hold time and hopper residence time.
• Assay and content-uniformity performance across beginning, middle, and end of encapsulation runs.

Norethindrone acetate is present at a higher dose but remains a low-dose pharmaceutical ingredient. Its distribution can still be affected by density differences between the hormone, lactose, starch, talc, and lubricant.

A robust platform would use a preblend or ordered-mixing process rather than adding micronized ethinyl estradiol directly to the full excipient load. Granulation could improve segregation control, but it introduces moisture, heat, and scale-up risks. Direct blending is commercially attractive when powder flow and low-dose uniformity are demonstrated without excessive lubricant.

Dissolution and disintegration

The product is an immediate-release capsule. The excipient system should provide:

• Rapid shell rupture.
• Fast wetting of hydrophobic hormone particles.
• Consistent dispersion of the active ingredients.
• No clinically relevant dissolution delay from magnesium stearate over-lubrication.
• Reproducible performance after storage under high humidity.

A developer should screen lactose grade, starch level, lubricant concentration, and capsule-shell composition against dissolution profiles. A formulation that meets assay requirements but shows slower dissolution after accelerated stability exposure may create a bioequivalence risk.

Moisture and photostability

Ethinyl estradiol and norethindrone acetate require protection from formulation and packaging conditions that promote degradation. Gelatin capsules can exchange moisture with the environment. Relevant controls include:

• Low-moisture excipient grades.
• Controlled capsule-shell water content.
• Light-protective blister materials.
• Desiccant or high-barrier bottle packaging where justified.
• Stability testing in the marketed configuration.
• Control of iron-related interactions during the 24/4 package cycle.

The iron capsules should be evaluated separately from the hormone capsules for moisture uptake, discoloration, odor, and capsule-shell interaction. The use of different shell colors for active and iron capsules can reduce dosing errors and improve regimen recognition.

What formulation patents protect Taytulla?

Taytulla’s protection is based on the drug product, dosage regimen, formulation, and FDA regulatory exclusivity rather than on new chemical entity protection for norethindrone acetate or ethinyl estradiol.

Public FDA labeling identifies Taytulla as NDA 209252. Orange Book records should be used to confirm the current listed patents, pediatric exclusivity, and any active patent-term adjustments.[1,2] Product-specific patent analysis should distinguish:

1. Composition or formulation patents covering the combined capsule product.
2. Method-of-use patents covering contraception or dosing.
3. Packaging or regimen patents, if listed.
4. Process patents that may affect manufacturing but may not appear in the Orange Book.
5. Regulatory exclusivity independent of patent rights.

Orange Book and Paragraph IV status

A generic applicant seeking approval before expiration of a listed patent may file a Paragraph IV certification. That certification can trigger patent litigation if the NDA holder sues within the statutory period after receiving notice.[3]

For Taytulla, the relevant commercial questions are:

Issue	Commercial impact
Listed product patents	Can delay final ANDA approval or launch
Paragraph IV certification	Creates litigation and possible 30-month stay
Paragraph III certification	Defers approval until patent expiry
Non-infringement or invalidity position	Determines launch risk
180-day exclusivity	May create first-filer advantage where applicable
Pediatric exclusivity	Can extend relevant regulatory protection by six months
Unlisted process patents	May require alternative manufacturing routes

The presence of a listed patent does not establish enforceability. A generic applicant may design around a formulation claim, challenge validity, or rely on a different excipient ratio while preserving the same active ingredients and dosage form.

When does Taytulla lose exclusivity?

Taytulla’s market exclusivity depends on the interaction of Orange Book patents, pediatric exclusivity, regulatory exclusivity, litigation outcomes, and ANDA approval timing. A fixed commercial entry date cannot be stated solely from the product launch date.

The FDA-approved product was introduced in 2017, but that date does not determine patent expiration. Patent terms generally run 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and pediatric exclusivity.[2,4]

Generic entry can occur before the nominal expiration of every patent if:

• The applicant receives approval after a successful Paragraph IV challenge.
• The listed patent is not infringed by the proposed product.
• The patent is invalidated or disclaimed.
• The patent is removed or no longer blocks approval.
• The applicant obtains a settlement-based launch license.

What generic entry risks exist for Taytulla?

The generic threat is meaningful because the active ingredients are established, orally administered, and supported by conventional ANDA principles. The principal risks are formulation execution and market economics.

Technical generic risks

A generic capsule must reproduce the relevant pharmaceutical performance without necessarily copying every excipient. High-risk areas include:

• Ethinyl estradiol content uniformity.
• Bioequivalence for a low-dose combination product.
• Dissolution under multiple pH conditions.
• Capsule-shell moisture and brittleness.
• Active-versus-iron capsule identification.
• Packaging line segregation between the two capsule types.
• Stability of hormone capsules in high-barrier packaging.
• Ferrous fumarate assay and impurity control.
• Product-color consistency across commercial lots.

Commercial generic risks

Taytulla competes with lower-cost norethindrone acetate/ethinyl estradiol products, including tablet formulations and other capsule products. A generic may face:

• Low reimbursement differentiation.
• Substitution pressure from established oral contraceptive suppliers.
• Limited physician loyalty to the branded capsule.
• Price erosion after multiple ANDA approvals.
• Inventory complexity from a 24-active/4-iron regimen.
• Lower net pricing despite a premium for capsule delivery.

The product may retain a niche among patients who prefer capsules, require the specific 24/4 regimen, or value iron-containing placebo capsules. That niche is commercially smaller than the overall combined oral contraceptive market.

What commercial opportunities exist for excipient suppliers?

The best opportunities are specialized rather than commodity-based.

Low-dose premix systems

Excipient suppliers can develop prequalified or co-processed systems for low-dose hormone blending. Potential value propositions include:

• Improved content uniformity.
• Reduced segregation.
• Better powder flow.
• Lower capsule-fill variability.
• Reduced operator handling of micronized hormone.
• Easier scale-up from development to commercial equipment.

A supplier that can demonstrate performance with norethindrone acetate and ethinyl estradiol has a stronger position than one selling generic lactose or magnesium stearate alone.

Direct-compression and capsule-fill platforms

Co-processed lactose-starch or silicified excipient systems could reduce the number of raw materials and improve flow. The formulation must preserve rapid disintegration and avoid excessive hydrophobicity from lubricant use.

Potential customers include generic manufacturers, contract development and manufacturing organizations, and companies developing oral contraceptive reformulations.

Capsule-shell technology

Commercial opportunities include:

• Lower-moisture gelatin shells.
• Hypromellose shells for customers avoiding gelatin.
• Improved color differentiation between active and iron capsules.
• Light-protective shell systems.
• Shells compatible with high-speed filling and blister packaging.

A gelatin-free product would create a potential differentiation pathway, but it would require a new formulation and bioequivalence strategy rather than a simple excipient substitution.

High-barrier packaging

Packaging suppliers can target:

• Cold-form aluminum blisters.
• High-barrier PVC/PVdC systems.
• Aluminum-aluminum blisters.
• Unit-dose calendar packs.
• Packaging with color-coded active and iron capsules.
• Child-resistant systems for bottle presentations.

Packaging can also support adherence. The 24/4 regimen is easier to communicate when the blister physically separates active and iron capsules and displays day-of-week labels.

Can Taytulla be reformulated into new dosage forms?

Yes, but each option creates a different regulatory and patent profile.

Reformulation	Commercial rationale	Main development barrier
Tablet version	Lower cost and established manufacturing	Loses capsule differentiation
Softgel capsule	Potentially improved hormone dispersion	New excipient, shell, and stability package
Hypromellose hard capsule	Gelatin-free positioning	Moisture and dissolution comparability
Chewable dosage form	Patient convenience	Taste masking and hormone stability
Smaller capsule	Swallowability	Fill-weight and content-uniformity constraints
Extended-cycle pack	Fewer withdrawal intervals	New regimen and clinical/regulatory requirements
Iron-free placebo pack	Simplified manufacturing	Changes product identity and labeling strategy

A 505(b)(2) pathway may be relevant to certain reformulations that rely on FDA findings for the reference product but introduce a new dosage form, regimen, or delivery system.[5] A conventional generic matching the reference capsule and active ingredients would generally be evaluated through the ANDA pathway.

How does Taytulla compare with competing oral contraceptives?

Product category	Active regimen	Dosage form	Excipient opportunity	Competitive position
Taytulla	Norethindrone acetate/ethinyl estradiol	Capsule, 24 active/4 iron	Low-dose blend, shell, packaging	Capsule and iron-placebo differentiation
Conventional norethindrone acetate/ethinyl estradiol	Same or similar hormones	Tablet	Low-cost direct compression	Strong generic substitution pressure
Drospirenone/ethinyl estradiol	Different progestin, often 24/4	Tablet	Particle engineering and dissolution	Competes on hormone profile
Levonorgestrel/ethinyl estradiol	Different progestin	Tablet	Commodity-scale formulation	Broad, price-sensitive market
Progestin-only products	No estrogen	Tablet or other forms	Moisture and low-dose uniformity	Alternative for estrogen-contraindicated patients

Taytulla’s defensible commercial attributes are dosage form, regimen design, and patient experience. Its excipient strategy should support those attributes without creating unnecessary cost.

What patent litigation and settlement issues affect commercial entry?

The key litigation trigger is a Paragraph IV notice against an Orange Book-listed patent. A settlement may establish a licensed generic entry date, authorize an authorized generic, or impose supply and launch restrictions. The relevant documents include:

• FDA Orange Book patent listings.
• Paragraph IV notice letters.
• District court complaints.
• Federal Circuit opinions.
• ANDA approval records.
• Settlement filings and antitrust review materials.

No commercial launch model should assume immediate substitution after patent expiry. Actual entry also depends on tentative or final ANDA approval, manufacturing readiness, state substitution rules, and payer contracting.

What is the revenue exposure for Taytulla?

Taytulla revenue is exposed to three forces:

1. Generic price competition.
2. Contraceptive switching among brands and formulations.
3. Payer preference for lower-cost tablet alternatives.

The most valuable commercial segment is likely the patient population that prefers capsules or the specific 24 active/4 iron regimen. Revenue protection therefore depends on adherence-oriented packaging, reliable availability, patient-support programs, and differentiation that generic tablets cannot replicate easily.

For excipient and CDMO businesses, the addressable opportunity is broader than Taytulla sales. A validated low-dose capsule platform can be adapted to other hormone products, low-dose steroids, and combination products requiring tight content uniformity.

How strong is the Taytulla patent estate?

The estate should be classified as moderate rather than dominant. The active ingredients are old, and multiple competing contraceptive formulations exist. The strongest potential barriers are product-specific formulation claims, regulatory exclusivity, and manufacturing know-how around capsule uniformity and regimen packaging.

The weakest barriers are commodity excipient selection and ordinary capsule technology. A competitor can usually substitute excipients if it maintains pharmaceutical equivalence, bioequivalence, stability, and acceptable dissolution.

Key Takeaways

• Taytulla contains 24 active capsules with norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, followed by four ferrous fumarate capsules.[1]
• The highest-value excipient problem is uniform delivery of microgram-level ethinyl estradiol.
• Premix systems, co-processed fillers, low-moisture capsule shells, and high-barrier packaging offer the clearest supplier opportunities.
• Generic entry risk is significant because the active ingredients are established and suitable for ANDA development.
• Formulation, method-of-use, packaging, and process patents must be analyzed separately.
• Taytulla’s commercial differentiation is primarily the capsule dosage form and 24/4 iron-containing regimen.
• Reformulations may use an ANDA or 505(b)(2) strategy depending on the degree of change.[5]
• The most durable excipient value lies in validated manufacturing performance, not in commodity ingredient supply.

FAQs

What excipient is most important for Taytulla content uniformity?

The most important issue is the complete formulation system, particularly the premixing process and filler selection used to distribute 20 mcg of ethinyl estradiol. No single excipient guarantees content uniformity.

Does ferrous fumarate in Taytulla act as a contraceptive ingredient?

No. Ferrous fumarate is used in the four capsules following the 24 active hormone capsules. It does not provide contraceptive activity.[1]

Could a generic Taytulla use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements.

Is Taytulla more difficult to manufacture than a conventional contraceptive tablet?

It can be. The product requires two capsule populations, low-dose hormone blending, iron-containing capsules, regimen differentiation, and packaging controls for a 24/4 schedule.

Which packaging format best protects a Taytulla-type product?

High-barrier blister packaging is generally attractive because it supports moisture and light protection, calendar dosing, capsule differentiation, and adherence. The final choice depends on stability data, cost, and market requirements.

References

1. U.S. Food and Drug Administration. (2017). Taytulla (norethindrone acetate and ethinyl estradiol capsules, and ferrous fumarate capsules) prescribing information. NDA 209252.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

4. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance. USPTO.

5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.